Biosceptre

Biosceptre Interviewed by Pharmaventures at Sachs Associates Conference, Basel

Biosceptre2019-12-12T15:21:10+11:00October 27th, 2016|News|

28th September, 2016 Daniel Barton spoke with Fintan Walton of [...]

Biosceptre2020-05-12T10:35:05+10:00July 27th, 2016|News|

Press Release - Biosceptre announces today that Professor Francesco Di [...]

Biosceptre2019-12-12T15:11:51+11:00June 13th, 2016|News|

Biosceptre represented at the 2nd Annual Immuno-Oncology: BD&L and Investment [...]

Biosceptre2019-12-12T15:01:31+11:00May 30th, 2016|News|

Biosceptre announces today that Sir Gregory Winter, founder of Cambridge [...]

Biosceptre2016-02-25T05:04:45+11:00February 25th, 2016|News|

Cambridge, UK, 8^th February 2016 – Biosceptre, a biopharmaceutical company developing

Biosceptre2014-10-20T09:00:29+11:00October 20th, 2014|Corporate|

Cambridge, UK, 20 October 2014. Biosceptre, the oncology company developing antibody products

Biosceptre2014-07-23T07:00:42+10:00July 23rd, 2014|Clinical|

Cambridge, UK, 23rd July 2014. Biosceptre, the oncology company developing antibody products

Biosceptre2014-07-18T09:00:52+10:00July 18th, 2014|Clinical, Corporate|

Paper concludes Biosceptre's target nf-P2X7 is ubiquitous to all cancer [...]

Biosceptre2014-07-16T07:00:24+10:00July 16th, 2014|Corporate|

Award to develop new therapeutic antibodies targeting nf-P2X7 to treat cancer [...]

Biosceptre2014-07-09T00:00:48+10:00July 9th, 2014|Clinical, Financial|

Funds to progress Phase I development of oncology product BIL-03s [...]